Sort   by:  
 Page size 
UnknownA multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia.
Not available
S-EPMC6536847 | biostudies-literature
UnknownAssociation of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial.
Not available
S-EPMC9577883 | biostudies-literature
UnknownTau as a diagnostic instrument in clinical trials to predict amyloid in Alzheimer's disease.
Not available
S-EPMC10432878 | biostudies-literature
UnknownEarly tau detection in flortaucipir images: validation in autopsy-confirmed data and implications for disease progression.
Not available
S-EPMC9972744 | biostudies-literature
UnknownPosttreatment Amyloid Levels and Clinical Outcomes Following Donanemab for Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
Not available
S-EPMC12687091 | biostudies-literature
UnknownTau PET in autosomal dominant Alzheimer's disease: relationship with cognition, dementia and other biomarkers.
Not available
S-EPMC6439328 | biostudies-literature
UnknownPET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer's disease and Lewy body disorders.
Not available
S-EPMC4027995 | biostudies-literature
UnknownImproving CSF biomarker accuracy in predicting prevalent and incident Alzheimer disease.
Not available
S-EPMC3053181 | biostudies-literature
UnknownComplementary value of molecular, phenotypic, and functional aging biomarkers in dementia prediction.
Not available
S-EPMC11979055 | biostudies-literature
UnknownAssociation of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial.
Not available
S-EPMC9468959 | biostudies-literature
Sort   by:  
 Page size